Savara Inc (NASDAQ:SVRA) Stock Position Lifted by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in shares of Savara Inc (NASDAQ:SVRA) by 7.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 140,010 shares of the company’s stock after purchasing an additional 9,180 shares during the period. Victory Capital Management Inc.’s holdings in Savara were worth $594,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its position in Savara by 95.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock valued at $134,000 after buying an additional 15,423 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Savara in the 3rd quarter worth approximately $192,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of Savara in the second quarter valued at approximately $215,000. Nantahala Capital Management LLC increased its stake in shares of Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the period. Finally, Algert Global LLC raised its holdings in Savara by 21.0% during the second quarter. Algert Global LLC now owns 238,807 shares of the company’s stock worth $962,000 after purchasing an additional 41,377 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SVRA. Evercore ISI reiterated an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. Finally, HC Wainwright cut their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Insider Activity

In related news, Director Joseph S. Mccracken purchased 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.13% of the stock is currently owned by corporate insiders.

Savara Price Performance

SVRA stock opened at $3.47 on Friday. The firm has a 50-day moving average of $3.68 and a two-hundred day moving average of $4.09. The firm has a market capitalization of $595.52 million, a PE ratio of -8.07 and a beta of 1.02. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a one year low of $2.82 and a one year high of $5.70.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.